Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers

Date

21 Oct 2023

Session

Poster session 16

Topics

Cancer Biology;  Pathology/Molecular Biology

Tumour Site

Breast Cancer

Presenters

Anna Karlsson

Citation

Annals of Oncology (2023) 34 (suppl_2): S1190-S1201. 10.1016/S0923-7534(23)01928-2

Authors

A. Karlsson1, F. Killander2, D. F. Nacer3, J. Häkkinen3, F. Rosengren3, J. Vallon-Christersson4, J. Staaf1

Author affiliations

  • 1 Translational Cancer Research, Lund University - Faculty of Medicine, 22381 - Lund/SE
  • 2 Department Of Clinical Sciences In Lund, Lund University - Faculty of Medicine, 22381 - Lund/SE
  • 3 Clinical Sciences, Lund, Lund University, 22220 - Lund/SE
  • 4 Division Of Oncology Department Of Clinical Sciences, Lund University, 22220 - Lund/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2333P

Background

The aim of this study was to investigate the correlation of BRCA1 promoter methylation status (BRCA1met) in patients with triple-negative breast cancer (TNBC) to clinicopathological and molecular variables, patient prognosis, patient response to neoadjuvant chemotherapy (NAC), and potential therapy resistance mechanisms in NAC treated patients.

Methods

145 patients enrolled 2015-2018 in the Sweden Cancerome Analysis Network - Breast (SCAN-B) study (ClinicalTrials.gov ID NCT02306096) were included. 109 had chemotherapy (>90% with sequential epirubicin + cyclophosphamide and a taxane, EC–T) according to national guidelines either as NAC (32%) or adjuvant (68%) therapy. Pathogenic BRCA1/2 variants were detected in 11 of 54 cases. Microsatellite instability and BRCA1met using pyrosequencing were investigated in all cases, including analyses of pre-treatment biopsies and surgical resections for NAC patients with residual disease (RD). The NAC patient cohort was extended with six additional SCAN-B patients to further explore treatment response in relation to BRCA1met. Clinicopathological and molecular variables were obtained through clinical review and complementary RNA-seq data.

Results

MSI and BRCA1met was observed in 2% and 17% of patients, respectively. BRCA1met was correlated to younger age and the PAM50 Basal phenotype (92%) and was frequent (40%) in women without pathogenic BRCA1/2 germline variants. No association was observed between BRCA1met and distant recurrence-free interval in adjuvant treated patients (log-rank p=0.77), nor between BRCA1met and pathological response in NAC patients (p=0.69). BRCA1met NAC cases revealed differences in methylation level and BRCA1 mRNA expression in pre-treatment versus surgically resected tissue in patients with RD. No BRCA1 gene fusions were detected. Genetic alterations between pre-treatment vs surgically resected tissue are further analyzed using whole genome sequencing.

Conclusions

BRCA1met is associated with young age in TNBC but hold no predictive nor prognostic value in this patient cohort. We observe a difference in BRCA1met patterns and BRCA1 mRNA expression in NAC patients with RD that may potentially be related to treatment resistance.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.